LAURA MINQUINI
A polymath by nature, I started my career as a fashion editor before doing qualitative market reports for luxury groups like LVMH. I was the CEO of the first license-focused tech accessories brand in Europe working with Apple.
My obsession with menopause has led me to own the problem of women’s health research funding. AthenaDAO pioneered a novel funding mechanism to support scientific discovery that could lead to drugs or therapeutics in women’s health. I am particularly proud that our work in field building and due diligence led to funding a program that could lead to AI drug discovery for menopause, or a small molecule to treat Diminished Ovarian Reserve.
This fall, I launched AthenaBIO, a new non-profit to build infrastructure for data collection for the era of AI.
You can connect with me on X or LinkedIn.
Select writings on funding female biology:
LAURA MINQUINI
A polymath by nature, I started my career as a fashion editor before doing qualitative market reports for luxury groups like LVMH. I was the CEO of the first license-focused tech accessories brand in Europe working with Apple.
My obsession with menopause has led me to own the problem of women’s health research funding. AthenaDAO pioneered a novel funding mechanism to support scientific discovery that could lead to drugs or therapeutics in women’s health. I am particularly proud that our work in field building and due diligence led to funding a program that could lead to AI drug discovery for menopause, or a small molecule to treat Diminished Ovarian Reserve.
This fall, I launched AthenaBIO, a new non-profit to build infrastructure for data collection for the era of AI.
You can connect with me on X or LinkedIn.
Select writings on funding female biology:
LAURA MINQUINI
A polymath by nature, I started my career as a fashion editor before doing qualitative market reports for luxury groups like LVMH. I was the CEO of the first license-focused tech accessories brand in Europe working with Apple.
My obsession with menopause has led me to own the problem of women’s health research funding. AthenaDAO pioneered a novel funding mechanism to support scientific discovery that could lead to drugs or therapeutics in women’s health. I am particularly proud that our work in field building and due diligence led to funding a program that could lead to AI drug discovery for menopause, or a small molecule to treat Diminished Ovarian Reserve.
This fall, I launched AthenaBIO, a new non-profit to build infrastructure for data collection for the era of AI.
You can connect with me on X or LinkedIn.
Select writings on funding female biology: